

2B  
O I P JUN 10 2002  
PRACTICE IN THE UNITED STATES TRADEMARK OFFICE

Practitioner's Docket No. MPI01-021P1RNM

*MP*  
**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Maria Alexandra Glucksmann  
Application No.: 10/085,233 Group No.: 1645  
Filed: February 28, 2002 Examiner: N/A  
For: 93870, A HUMAN G-PROTEIN COUPLED RECEPTOR AND USES THEREFOR

**Box Sequence**  
**Assistant Commissioner for Patents**  
**P.O. Box 2327**  
**Arlington, VA 22202**

**SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY,  
AND/OR AMENDMENT PERTAINING THERETO  
FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE  
AND/OR AMINO ACID SEQUENCE**

1.  This replies to the Notice to File Missing Parts of Nonprovisional Application with Raw Sequence Listing Error Report dated April 11, 2002.
- A copy of the Notice to File Missing Parts of Nonprovisional Application with Raw Sequence Listing Error Report is enclosed.

**IDENTIFICATION OF PERSON MAKING STATEMENT**

2. I, Jean M. Silveri  
(*type or print name of person signing below*)

state the following:

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Box Sequence, P.O. Box 2327, Arlington, VA 22202.  
**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

- with sufficient postage as first class mail.  as "Express Mail Post Office to Address"  
Mailing Label No. \_\_\_\_\_

**TRANSMISSION**

- transmitted by facsimile to the Patent and Trademark Office.

*Simonne Corriveau*  
Signature

Date: 7 June 2002

Simonne Corriveau  
(*type or print name of person certifying*)

**\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.**

**ITEMS BEING SUBMITTED**

3. Submitted herewith is/are:

- A.  6 pages of "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. Section 1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.
- B.  An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. Section 1.821(d).
- C.  A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.
- D.  Please transfer to this application, in accordance with 37 C.F.R. Section 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of:

Application No.:

Group No.:

Filed:

Examiner:

For:

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form

"Sequence Identifier"

(other application)

(this application)

- E.  A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. Section 1.821(g).
  - Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. Section 1.821(b).

**Practitioner's Docket No. MPI01-021P1RNM**

F.  Because this submission is made in fulfilling the requirement under 37 C.F.R. Section 1.821(g), a statement that the submission includes no new matter.

Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. Section 1.821(g).

**STATEMENT THAT "SEQUENCE LISTING"  
AND COMPUTER READABLE COPY ARE THE SAME  
AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER**

4. I hereby state:

- A.  Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
- B.  All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

**EXTENSION OF TERM**

5. The proceedings herein are for a patent application and the provisions of 37 C.F.R. Section 1.136 apply.

(a)  Applicant petitions for an extension of time under 37 C.F.R. Section 1.136 (fees: 37 C.F.R. Section 1.17(a)(1)-(4)) for the total number of months checked below:

<u>Extension (months)</u>	<u>Fee for other than small entity</u>	<u>Fee for small entity</u>
<input type="checkbox"/> one month	\$ 110.00	\$ 55.00
<input type="checkbox"/> two months	\$ 390.00	\$ 195.00
<input type="checkbox"/> three months	\$ 890.00	\$ 445.00
<input type="checkbox"/> four months	\$1,390.00	\$ 695.00

**Fee    \$0.00**

If an additional extension of time is required, please consider this a petition therefor.

An extension for \_\_\_\_\_ months has already been secured, and the fee paid therefor of \$0.00 is deducted from the total fee due for the total months of extension now requested.

Extension fee due with this request \$0.00  
(Page 3 of 4)

**Practitioner's Docket No. MPI01-021P1RNM**

**OR**

- (b)  Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

**FEE PAYMENT**

6.  Attached is a check in the sum of \$\_\_\_\_\_.
- Charge Account No. 501668 the sum of \$0.00.  
A duplicate of this transmittal is attached.


**FEE DEFICIENCY**

8.  If any additional extension and/or fee is required, charge Account No. 501668.

7 June 2002

**MILLENNIUM PHARMACEUTICALS, INC.**

By

  
Jean M. Silveri  
Registration No. 39,030  
75 Sidney Street  
Cambridge, MA 02139  
Telephone - 617-679-7336  
Facsimile - 617-551-8820

## RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/085, 233  
Source: OIPE  
Date Processed by STIC: 3-12-2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: [patin3help@uspto.gov](mailto:patin3help@uspto.gov) or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>


Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>), EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:  
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name,  
Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202  
Or  
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,  
2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,  
Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002



OIPE

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/10/085,233

DATE: 03/12/2002  
TIME: 14:01:24

Input Set : A:\SEQUENCE LISTIN1.txt  
Output Set: N:\CRF3\03122002\J085233.raw

Does Not Comply  
Corrected Diskette Needed

4 <110> APPLICANT: GLUCKSMANN, MARIA ALEXANDRA  
6 <120> TITLE OF INVENTION: 93870, A HUMAN G-PROTEIN COUPLED  
7 RECEPTOR AND USES THEREFOR  
10 <130> FILE REFERENCE: MPI2001-021P1RCP1(M)  
C--> 12 <140> CURRENT APPLICATION NUMBER: US/10/085,233  
C--> 12 <141> CURRENT FILING DATE: 2002-02-28  
12 <150> PRIOR APPLICATION NUMBER: 60/272,677  
14 <151> PRIOR FILING DATE: 2001-03-01  
E--> 16 <160> NUMBER OF SEQ ID NOS: 5  
19 <170> SOFTWARE: FastSEQ for Windows Version 4.0

Number of sequences  
on CRF is 6 not

5

## ERRORED SEQUENCES

338 <210> SEQ ID NO: 6  
339 <211> LENGTH: 17  
340 <212> TYPE: PRT  
341 <213> ORGANISM: Artificial Sequence  
343 <220> FEATURE:  
344 <221> NAME/KEY: VARIANT  
345 <222> LOCATION: (1)...(1)  
346 <223> OTHER INFORMATION: The amino acid at position 1 can be S or T or A or  
347 L or I or V or M or F or Y or W or C  
349 <221> NAME/KEY: VARIANT  
350 <222> LOCATION: (2)...(2)  
351 <223> OTHER INFORMATION: The amino acid at position 2 can be S or T or A or  
352 N or P or D or E  
354 <221> NAME/KEY: VARIANT  
355 <222> LOCATION: (3)...(3)  
356 <223> OTHER INFORMATION: The amino acid at position 3 can not be E or D or  
357 P or K or R or H  
359 <223> OTHER INFORMATION: The amino acid at position 4 and at position 5 can  
360 be any amino acid  
362 <221> NAME/KEY: VARIANT  
363 <222> LOCATION: (6)...(6)  
364 <223> OTHER INFORMATION: The amino acid at position 6 can be I or V or M or  
365 N or Q or G or A  
367 <223> OTHER INFORMATION: The amino acid at position 7 and at position 8 can  
368 be any amino acid  
370 <221> NAME/KEY: VARIANT  
371 <222> LOCATION: (9)...(9)  
372 <223> OTHER INFORMATION: The amino acid at position 9 can be I or V or M or  
373 F or T

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/10/085,233

DATE: 03/12/2002  
TIME: 14:01:24

Input Set : A:\SEQUENCE LISTIN1.txt  
Output Set: N:\CRF3\03122002\J085233.raw

375 <221> NAME/KEY: VARIANT  
376 <222> LOCATION: (10)...(10)  
377 <223> OTHER INFORMATION: The amino acid at position 10 can be S or T or A or  
378 N or C  
380 <221> NAME/KEY: VARIANT  
381 <222> LOCATION: (11)...(11)  
382 <223> OTHER INFORMATION: The amino acid at position 11 can be I or V or M  
383 or F or Y or W or S or T or A or C  
385 <221> NAME/KEY: VARIANT  
386 <222> LOCATION: (12)...(12)  
387 <223> OTHER INFORMATION: The amino acid at position 12 can be E or N or H  
389 <221> NAME/KEY: VARIANT  
390 <222> LOCATION: (14)...(14)  
391 <223> OTHER INFORMATION: The amino acid at position 14 can be Y or W or C  
392 or S or H  
394 <223> OTHER INFORMATION: The amino acid at position 15 and at position 16  
395 can be any amino acid  
397 <221> NAME/KEY: VARIANT  
398 <222> LOCATION: (17)...(17)  
399 <223> OTHER INFORMATION: The amino acid at position 17 can be I or V or M  
401 <400> SEQUENCE: 6

W--> 402 Gly Gly Gly Xaa Xaa Leu Xaa Xaa Leu Gly Leu Asp Arg Phe Xaa Xaa  
403 1 5 10 15

404 Leu

E--> 409 - 1 -

VERIFICATION SUMMARY  
PATENT APPLICATION: US/10/085,233

DATE: 03/12/2002  
TIME: 14:01:25

Input Set : A:\SEQUENCE LISTIN1.txt  
Output Set: N:\CRF3\03122002\J085233.raw

L:12 M:270 C: Current Application Number differs, Replaced Current Application No  
L:12 M:271 C: Current Filing Date differs, Replaced Current Filing Date  
L:120 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1  
L:402 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6  
L:409 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:6  
L:16 M:203 E: No. of Seq. differs, <160> Number Of Sequences:Input (5) Counted (6)